Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Venous thromboembolism in 2013: the advent of the novel oral anticoagulants.

Literature DB >> 24419256

Venous thromboembolism in 2013: the advent of the novel oral anticoagulants.

Abstract

New findings published in 2013 strongly support the use of novel oral anticoagulants in the treatment of thromboembolic disorders. These drugs have been shown to have a more-favourable benefit-to-risk profile than older compounds, enabling their use from the start of treatment and in the whole spectrum of clinical presentations.

Entities: Disease

Mesh：

Substances：
Anticoagulants

Year: 2014 PMID： 24419256 DOI： 10.1038/nrcardio.2013.210

Source DB: PubMed Journal: Nat Rev Cardiol ISSN： 1759-5002 Impact factor: 32.419

10 in total

1. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.

Authors: Harry R Büller; Hervé Décousus; Michael A Grosso; Michele Mercuri; Saskia Middeldorp; Martin H Prins; Gary E Raskob; Sebastian M Schellong; Lee Schwocho; Annelise Segers; Minggao Shi; Peter Verhamme; Phil Wells
Journal: N Engl J Med Date: 2013-08-31 Impact factor: 91.245

Review 2. The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities.

Authors: Paolo Prandoni; Sofia Barbar; Marta Milan; Valentina Vedovetto; Raffaele Pesavento
Journal: Eur J Intern Med Date: 2013-10-09 Impact factor: 4.487

3. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

Authors: Harry R Büller; Martin H Prins; Anthonie W A Lensin; Hervé Decousus; Barry F Jacobson; Erich Minar; Jaromir Chlumsky; Peter Verhamme; Phil Wells; Giancarlo Agnelli; Alexander Cohen; Scott D Berkowitz; Henri Bounameaux; Bruce L Davidson; Frank Misselwitz; Alex S Gallus; Gary E Raskob; Sebastian Schellong; Annelise Segers
Journal: N Engl J Med Date: 2012-03-26 Impact factor: 91.245

4. Oral apixaban for the treatment of acute venous thromboembolism.

Authors: Giancarlo Agnelli; Harry R Buller; Alexander Cohen; Madelyn Curto; Alexander S Gallus; Margot Johnson; Urszula Masiukiewicz; Raphael Pak; John Thompson; Gary E Raskob; Jeffrey I Weitz
Journal: N Engl J Med Date: 2013-07-01 Impact factor: 91.245

5. Oral rivaroxaban for symptomatic venous thromboembolism.

Authors: Rupert Bauersachs; Scott D Berkowitz; Benjamin Brenner; Harry R Buller; Hervé Decousus; Alex S Gallus; Anthonie W Lensing; Frank Misselwitz; Martin H Prins; Gary E Raskob; Annelise Segers; Peter Verhamme; Phil Wells; Giancarlo Agnelli; Henri Bounameaux; Alexander Cohen; Bruce L Davidson; Franco Piovella; Sebastian Schellong
Journal: N Engl J Med Date: 2010-12-03 Impact factor: 91.245

6. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients.

Authors: Paolo Prandoni; Franco Noventa; Angelo Ghirarduzzi; Vittorio Pengo; Enrico Bernardi; Raffaele Pesavento; Matteo Iotti; Daniela Tormene; Paolo Simioni; Antonio Pagnan
Journal: Haematologica Date: 2007-02 Impact factor: 9.941

7. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.

Authors: Sam Schulman; Clive Kearon; Ajay K Kakkar; Sebastian Schellong; Henry Eriksson; David Baanstra; Anne Mathilde Kvamme; Jeffrey Friedman; Patrick Mismetti; Samuel Z Goldhaber
Journal: N Engl J Med Date: 2013-02-21 Impact factor: 91.245

8. Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

Authors: Sam Schulman; Clive Kearon; Ajay K Kakkar; Patrick Mismetti; Sebastian Schellong; Henry Eriksson; David Baanstra; Janet Schnee; Samuel Z Goldhaber
Journal: N Engl J Med Date: 2009-12-10 Impact factor: 91.245

Review 9. Pulmonary embolism: risk assessment and management.

Authors: Stavros Konstantinides; Samuel Z Goldhaber
Journal: Eur Heart J Date: 2012-09-07 Impact factor: 29.983

10. Apixaban for extended treatment of venous thromboembolism.

Authors: Giancarlo Agnelli; Harry R Buller; Alexander Cohen; Madelyn Curto; Alexander S Gallus; Margot Johnson; Anthony Porcari; Gary E Raskob; Jeffrey I Weitz
Journal: N Engl J Med Date: 2012-12-08 Impact factor: 91.245

10 in total

5 in total

Venous thromboembolism in 2013: the advent of the novel oral anticoagulants.

1. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.

Review 2. The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities.

3. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

4. Oral apixaban for the treatment of acute venous thromboembolism.

5. Oral rivaroxaban for symptomatic venous thromboembolism.

6. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients.

7. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.

8. Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

Review 9. Pulmonary embolism: risk assessment and management.

10. Apixaban for extended treatment of venous thromboembolism.

Review 1. The treatment of venous thromboembolism with novel oral anticoagulants: warnings and limitations.

2. The use of novel oral anticoagulants: the debate continues!

Review 3. The value of inhibitors of factor Xa for the treatment of pulmonary embolism.

4. Blood transfusions and hip fracture mortality - A retrospective cohort study.

5. Lyso-Sulfatide Binds Factor Xa and Inhibits Thrombin Generation by the Prothrombinase Complex.